Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR

杜瓦卢马布 医学 放化疗 阶段(地层学) 内科学 肿瘤科 放射治疗 癌症 古生物学 免疫疗法 无容量 生物
作者
Cheol‐Kyu Park,Hyung‐Joo Oh,Young‐Chul Kim,Yong-Hyub Kim,Sung‐Ja Ahn,Won Gi Jeong,Jeong Yeop Lee,Jae Cheol Lee,Chang‐Min Choi,Wonjun Ji,Si Yeol Song,Juwhan Choi,Sung Yong Lee,Hakyoung Kim,Shin Yup Lee,Jongmoo Park,Seong Hoon Yoon,Ji Hyeon Joo,In‐Jae Oh
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (8): 1042-1054 被引量:14
标识
DOI:10.1016/j.jtho.2023.04.008
摘要

IntroductionThis study aimed to investigate real-world evidence for efficacy and safety of durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC.MethodsPatients with stage III NSCLC who started DC after CRT between September 2018 and December 2020 and were treated at five tertiary hospitals in the Republic of Korea were included. The primary end point was real-world progression-free survival (rwPFS). Secondary end points were overall survival, objective response rate, and adverse events including radiation pneumonitis (RP) and immune-related adverse events (irAEs).ResultsA total of 157 patients were enrolled. At the median follow-up of 19.1 months, median rwPFS of DC was 25.9 months (95% confidence interval: 16.5–35.4) and the 1-, 2-, and 3-year rwPFS rates were 59.4%, 51.8%, and 43.5%, respectively. The median overall survival was not mature, and objective response rate of DC was 51.0%. High programmed death-ligand 1 expression (≥50%) and development of RP requiring steroid treatment were significantly associated with longer (p = 0.043) and shorter rwPFS (p = 0.036), respectively. RP, RP requiring steroid treatment, and irAEs developed in 57 (36.3%), 42 (26.8%), and 53 (33.8%) patients, respectively. Among peripheral blood cell counts at the initiation of DC, a high derived monocyte-to-lymphocyte ratio was the most significant risk factor for the development of RP requiring steroid treatment (OR 44.76, 95% CI: 8.89–225.43, p < 0.001) and irAEs (OR 2.85, 95% CI: 1.27–6.41, p = 0.011).ConclusionsCompared with the outcome of the PACIFIC trial, these real-world data revealed favorable survival benefits of DC after CRT in patients with unresectable stage III NSCLC. Blood-based biomarkers could predict higher-grade RP and irAEs before the initiation of DC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wtdd完成签到,获得积分20
1秒前
1秒前
尊敬寒松发布了新的文献求助10
2秒前
研友_Lw4Emn完成签到,获得积分10
3秒前
肯瑞恩哭哭完成签到,获得积分10
3秒前
tingting完成签到 ,获得积分10
4秒前
4秒前
肉卷发布了新的文献求助10
5秒前
6秒前
6秒前
2758543477完成签到,获得积分10
7秒前
和珈欢乐完成签到,获得积分10
7秒前
8秒前
Honcy发布了新的文献求助10
9秒前
小牧鱼完成签到,获得积分10
10秒前
GIA完成签到,获得积分10
11秒前
活力的小猫咪完成签到 ,获得积分10
14秒前
18秒前
18秒前
19秒前
19秒前
海棠听风完成签到 ,获得积分10
19秒前
英俊的铭应助李Sir采纳,获得10
20秒前
AaronDP发布了新的文献求助100
22秒前
Lee发布了新的文献求助10
23秒前
天天快乐应助1111采纳,获得10
23秒前
xi完成签到,获得积分20
24秒前
大模型应助dream采纳,获得10
24秒前
科目三应助UniTTEC9560采纳,获得10
24秒前
aa关闭了aa文献求助
25秒前
吃饭吧完成签到,获得积分10
25秒前
lifeup发布了新的文献求助10
27秒前
隐形曼青应助俭朴的一曲采纳,获得10
27秒前
CKK发布了新的文献求助10
27秒前
田一完成签到,获得积分10
30秒前
研友_Lw4Emn关注了科研通微信公众号
30秒前
Jasper应助qmx采纳,获得10
31秒前
小王完成签到,获得积分20
31秒前
枝枝桃桃发布了新的文献求助10
31秒前
通通完成签到,获得积分10
33秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 1030
A new approach to the extrapolation of accelerated life test data 1000
Indomethacinのヒトにおける経皮吸収 400
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 370
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3993903
求助须知:如何正确求助?哪些是违规求助? 3534470
关于积分的说明 11265717
捐赠科研通 3274344
什么是DOI,文献DOI怎么找? 1806358
邀请新用户注册赠送积分活动 883170
科研通“疑难数据库(出版商)”最低求助积分说明 809712